202 related articles for article (PubMed ID: 30620386)
1. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.
Wong W; Lowery MA; Berger MF; Kemel Y; Taylor B; Zehir A; Srinivasan P; Bandlamudi C; Chou J; Capanu M; Varghese A; Yu KH; Iacobuzio-Donahue CA; Shia J; Klimstra DS; Jarnagin WR; Stadler ZK; O'Reilly EM
Cancer; 2019 May; 125(9):1441-1448. PubMed ID: 30620386
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
[TBL] [Abstract][Full Text] [Related]
3. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2).
Hechtman JF; Liu W; Sadowska J; Zhen L; Borsu L; Arcila ME; Won HH; Shah RH; Berger MF; Vakiani E; Shia J; Klimstra DS
Mod Pathol; 2015 Aug; 28(8):1123-9. PubMed ID: 25975284
[TBL] [Abstract][Full Text] [Related]
4. Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
Maynard H; Stadler ZK; Berger MF; Solit DB; Ly M; Lowery MA; Mandelker D; Zhang L; Jordan E; El Dika I; Kemel Y; Ladanyi M; Robson ME; O'Reilly EM; Abou-Alfa GK
Cancer; 2020 Jan; 126(9):1995-2002. PubMed ID: 32012241
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
6. Identification and prevalence of potentially therapeutic targetable variants of major cancer driver genes in ampullary cancer patients in India through deep sequencing.
Mishra SK; Kumari N; Krishnani N; Singh RK; Mohindra S
Cancer Genet; 2021 Nov; 258-259():41-48. PubMed ID: 34455261
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
8. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
9. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
10. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.
Overman MJ; Soifer HS; Schueneman AJ; Ensor J; Adsay V; Saka B; Neishaboori N; Wolff RA; Wang H; Schnabel CA; Varadhachary G
BMC Cancer; 2016 Aug; 16(1):668. PubMed ID: 27549176
[TBL] [Abstract][Full Text] [Related]
11. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
12. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Lowery MA; Wong W; Jordan EJ; Lee JW; Kemel Y; Vijai J; Mandelker D; Zehir A; Capanu M; Salo-Mullen E; Arnold AG; Yu KH; Varghese AM; Kelsen DP; Brenner R; Kaufmann E; Ravichandran V; Mukherjee S; Berger MF; Hyman DM; Klimstra DS; Abou-Alfa GK; Tjan C; Covington C; Maynard H; Allen PJ; Askan G; Leach SD; Iacobuzio-Donahue CA; Robson ME; Offit K; Stadler ZK; O'Reilly EM
J Natl Cancer Inst; 2018 Oct; 110(10):1067-1074. PubMed ID: 29506128
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas.
Harthimmer MR; Stolborg U; Pfeiffer P; Mortensen MB; Fristrup C; Detlefsen S
J Clin Pathol; 2019 Nov; 72(11):762-770. PubMed ID: 31256008
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma.
Asano E; Okano K; Oshima M; Kagawa S; Kushida Y; Munekage M; Hanazaki K; Watanabe J; Takada Y; Ikemoto T; Shimada M; Suzuki Y;
J Surg Oncol; 2016 Jul; 114(1):119-27. PubMed ID: 27132476
[TBL] [Abstract][Full Text] [Related]
15. Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Patel M; Uboha NV
Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
[TBL] [Abstract][Full Text] [Related]
16. Survival in ampullary cancer: potential role of different KRAS mutations.
Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.
Soumerai TE; Donoghue MTA; Bandlamudi C; Srinivasan P; Chang MT; Zamarin D; Cadoo KA; Grisham RN; O'Cearbhaill RE; Tew WP; Konner JA; Hensley ML; Makker V; Sabbatini P; Spriggs DR; Troso-Sandoval TA; Charen AS; Friedman C; Gorsky M; Schweber SJ; Middha S; Murali R; Chiang S; Park KJ; Soslow RA; Ladanyi M; Li BT; Mueller J; Weigelt B; Zehir A; Berger MF; Abu-Rustum NR; Aghajanian C; DeLair DF; Solit DB; Taylor BS; Hyman DM
Clin Cancer Res; 2018 Dec; 24(23):5939-5947. PubMed ID: 30068706
[TBL] [Abstract][Full Text] [Related]
18. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
[TBL] [Abstract][Full Text] [Related]
19. Advances in Molecular Pathology and Treatment of Periampullary Cancers.
Chandrasegaram MD; Chen JW; Price TJ; Zalcberg J; Sjoquist K; Merrett ND
Pancreas; 2016 Jan; 45(1):32-9. PubMed ID: 26348463
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
